CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs) targeting programmed cell death receptor-1 (PD-1) or its ligand (PD-L1) have substantially improved the clinical outcomes of driver-negative non-small-cell lung cancer (NSCLC) patients [1–4].